Semaglutide vs Tirzepatide: What's the Difference?

If you've been following the world of GLP-1 weight loss medications, you've almost certainly heard the names semaglutide and tirzepatide — the active ingredients behind some of the most talked-about drugs in modern medicine. But these two medications aren't the same, and the differences go well beyond the brand name on the box. Let's break down who makes them, how they work in your body, what the research says about weight loss results, and what a shift in delivery method could mean for millions of people who struggle with injections.

Who Makes Each Medication?

Semaglutide is manufactured by Novo Nordisk, a Danish pharmaceutical company with decades of experience in diabetes and metabolic disease. You may know semaglutide under its brand names: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management).

Tirzepatide is manufactured by Eli Lilly and Company, one of the largest pharmaceutical companies in the United States. Tirzepatide is sold under two brand names: Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management and, more recently, obstructive sleep apnea).

How to Get Tirzepatide: LillyDirect

One of the most patient-friendly innovations to come out of the GLP-1 space is LillyDirect, Eli Lilly's direct-to-consumer digital health platform. Launched in early 2024, LillyDirect allows patients with a valid prescription to access Zepbound (tirzepatide) at transparent self-pay pricing without going through insurance or a traditional retail pharmacy markup.

Through LillyDirect's Zepbound Self Pay Journey Program, patients can currently access all approved strengths of Zepbound single-dose vials starting at $299/month for the 2.5 mg starting dose, with higher maintenance doses available for $399–$449/month. The platform integrates home delivery and savings support in one streamlined experience. Lilly has even expanded the program to Walmart pharmacy pickup locations nationwide, making it even more accessible for those who prefer in-person pickup.

How to Get Semaglutide: NovoCare Pharmacy

If you're wondering whether Novo Nordisk offers something similar to LillyDirect for semaglutide, the answer is yes, and it arrived more recently. In March 2025, Novo Nordisk launched NovoCare Pharmacy, a direct-to-patient delivery program that offers all dose strengths of Wegovy (injectable semaglutide) at a self-pay price ranging from $199/month to $349/month (depending on dose) for cash-paying patients who are uninsured or whose commercial insurance doesn't cover obesity medications.

Like LillyDirect, NovoCare Pharmacy ships authentic, FDA-approved Wegovy directly to patients' homes — fulfilled through CenterWell Pharmacy. Patients can also access benefit verification, refill reminders, and live support from a NovoCare case manager. One key difference from LillyDirect: NovoCare Pharmacy is currently a cash-pay only program and does not accept commercial insurance, whereas LillyDirect accepts most health insurance plans for select medications in addition to its self-pay option.

Both programs represent a significant shift in how these medications reach patients, cutting out middlemen and offering pricing that is far below the original list prices (Wegovy's list price was previously $1,349/month before these programs launched).

How Each Drug Works: The Receptor Story

To understand why tirzepatide has generated such excitement in clinical trials, you need to understand the receptors each drug targets.

Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a naturally occurring hormone released after eating. GLP-1 receptors are found in the brain (particularly in areas that regulate appetite and satiety), the pancreas (where GLP-1 stimulates insulin release in a glucose-dependent manner), and the stomach (where it slows gastric emptying). By activating GLP-1 receptors, semaglutide reduces hunger signals, slows how quickly food leaves your stomach, and helps regulate blood sugar.

Tirzepatide takes a different and more powerful approach. It is a dual agonist, meaning it activates two receptors simultaneously: the GLP-1 receptor (the same one semaglutide targets) and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that plays a role in the regulation of fat storage, insulin sensitivity, and adipose tissue metabolism. By targeting both GLP-1 and GIP receptors at the same time, tirzepatide produces a broader hormonal effect on appetite, energy balance, and fat utilization — which may help explain its edge in weight loss outcomes compared to GLP-1 mono-agonists like semaglutide.

Weight Loss Results: What the Studies Show

Injectable Semaglutide (Wegovy)

The landmark STEP-1 trial studied once-weekly injectable semaglutide 2.4 mg in adults with obesity (without type 2 diabetes) over 68 weeks. Participants achieved an average weight loss of approximately 14.9% of their body weight compared to placebo. About 73–92% of participants achieved at least 5% weight loss, depending on diabetes status.

Tirzepatide (Zepbound)

The SURMOUNT-1 trial, the corresponding trial for tirzepatide in adults without diabetes, demonstrated substantially greater results. At the maximum 15 mg dose, participants lost an average of 20.9% of their body weight over 72 weeks.

Head-to-Head: SURMOUNT-5

A landmark direct head-to-head trial called SURMOUNT-5 compared tirzepatide and semaglutide side-by-side in adults with obesity (without type 2 diabetes) over 72 weeks. The results, published in the New England Journal of Medicine, showed that participants on tirzepatide lost an average of 20.2% of their body weight, compared to 13.7% for semaglutide. Tirzepatide participants were also significantly more likely to achieve weight loss milestones of 10%, 15%, 20%, and 25% compared to those on semaglutide.

Tirzepatide also outperformed semaglutide in waist circumference reduction: 18.4 cm versus 13.0 cm on average.

Real-World Data Confirms the Advantage

A large real-world cohort study published in JAMA Internal Medicine analyzed over 18,000 matched patients and found that people using tirzepatide were significantly more likely to achieve 5%, 10%, and 15% weight loss thresholds than those using semaglutide. At 12 months, tirzepatide users had lost an average of 6.9 percentage points more body weight than semaglutide users in the same timeframe.

Side Effect Differences: Any Differences?

Both medications share a similar side effect profile, which is not surprising given that they both activate GLP-1 receptors. The most commonly reported adverse events with both drugs include:

• Nausea
• Diarrhea
• Vomiting
• Constipation

These gastrointestinal side effects are most common during the dose escalation phase, when the body is adjusting to higher doses, and tend to diminish over time. They are generally described as mild to moderate in severity.

Here's where it gets interesting: some analyses of Phase 3 trial data suggest that tirzepatide may actually produce fewer gastrointestinal side effects than injectable semaglutide at comparable doses, despite achieving greater weight loss. One systematic review found that tirzepatide 10 mg and 15 mg were associated with less frequent GI side effects compared to semaglutide 2.4 mg. Similarly, the SURMOUNT-5 head-to-head trial found that "GI adverse events in both groups were generally mild to moderate, with no significant differences in discontinuation rates."

However, the real-world JAMA Internal Medicine cohort study found that rates of gastrointestinal adverse events were similar between the groups, so the evidence here is still evolving. Both medications are generally well-tolerated, and the side effect experience can vary significantly from person to person.

Both medications also carry boxed warnings regarding the theoretical risk of thyroid C-cell tumors (based on animal studies), and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

The Rise of Oral Semaglutide: A Game-Changer for Needle-Averse Patients

One of the most exciting recent developments in the GLP-1 space is the FDA approval of an oral version of semaglutide for weight loss. In December 2025, the FDA approved the Wegovy pill (oral semaglutide) making it the first oral GLP-1 receptor agonist approved for chronic weight management in the United States.

The approval is based on data from the OASIS 4 trial, a 64-week Phase 3 study in adults with obesity or overweight (without diabetes). Participants who adhered to treatment achieved a mean weight loss of approximately 16.6% (comparable to the injectable Wegovy) while one in three adherent participants achieved at least 20% weight loss.

The oral Wegovy pill is available in dose strengths of 1.5 mg, 4 mg, 9 mg, and 25 mg, and does require a 30-minute waiting period after taking it before eating or drinking. It does not require refrigeration, unlike the injectable versions, which is a significant practical advantage. Novo Nordisk has priced the starting dose at $149/month, making it potentially the most affordable entry point into the GLP-1 weight loss space.

This is important for patients who may be hesitant about weekly injections, who travel frequently, or who simply prefer the convenience of a once-daily pill. While the injectable forms of semaglutide and tirzepatide currently demonstrate higher average weight loss in clinical trials, oral semaglutide now gives clinicians and patients another meaningful option to consider.

All materials contained in this blog post are for informational purposes only and should not be construed as medical advice. Please consult with your physician concerning any and all medical questions and/or problems.